Physician profile
Edward Lee
NPI 1669600326
$3,390.94
in general payments reported to CMS, 2019-2025
30 companies · $985 in 2025
The $985 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $97.22 · 2022: $955 · 2023: $466 · 2024: $888 · 2025: $985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,339.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $588.90 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $405.19 | 2022-2025 | |
| Lilly USA, LLC | $226.72 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $197.53 | 2022-2025 | Repatha, Otezla, Repatha |
| Phathom Pharmaceuticals, INC. | $188.92 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $179.55 | 2022-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $179.38 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $177.86 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $142.84 | 2022-2025 | |
| Pfizer INC. | $135.00 | 2023-2025 | |
| Glaxosmithkline, LLC. | $126.12 | 2022-2025 | Shingrix |
| Janssen Pharmaceuticals, INC | $112.21 | 2020-2023 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $97.82 | 2022-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.75 | 2022-2025 | Jardiance, Tradjenta, Synjardy |
| Exact Sciences Corporation | $81.63 | 2023-2025 | Cologuard Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $76.19 | 2022-2025 | Injectafer |
| Novartis Pharmaceuticals Corporation | $70.03 | 2022-2023 | |
| Nestle Healthcare Nutrition INC. | $50.57 | 2022 | |
| Dexcom, INC. | $41.43 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $33.68 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $30.17 | 2022-2025 | Zoryve |
| Merck Sharp & Dohme LLC | $26.06 | 2022-2025 | Capvaxive, Gardasil 9 |
| Inspire Medical Systems, INC. | $22.43 | 2024 | Inspire |
| Lundbeck LLC | $17.48 | 2024 | Rexulti |
| Corcept Therapeutics | $16.54 | 2025 | Korlym |
| Idorsia Pharmaceuticals US INC | $16.35 | 2023 | Quviviq |
| Evoke Pharma, INC. | $16.10 | 2023 | Gimoti |
| Optinose US, INC. | $15.33 | 2024 | |
| Astellas Pharma US INC | $15.16 | 2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.